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Abstract: Pancreatic cancer is a formidable malignancy with poor outcomes. The majority of 
patients are unable to undergo resection, which remains the only potentially curative treatment 
option. The management of locally advanced (unresectable) pancreatic cancer is controversial; 
however, treatment with either chemotherapy or chemoradiation is associated with high rates 
of local tumor progression and metastases development, resulting in low survival rates. An 
emerging local modality is stereotactic body radiation therapy (SBRT), which uses image-
guided, conformal, high-dose radiation. SBRT has demonstrated promising local control rates 
and resultant quality of life with acceptable rates of toxicity. Over the past decade, increasing 
clinical experience and data have supported SBRT as a local treatment modality. Nevertheless, 
additional research is required to further evaluate the role of SBRT and improve upon the per-
sistently poor outcomes associated with pancreatic cancer. This review discusses the existing 
clinical experience and technical implementation of SBRT for pancreatic cancer and highlights 
the directions for ongoing and future studies.
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Introduction
Pancreatic cancer is associated with a poor prognosis. It is estimated that 53,070 
new diagnoses of pancreatic cancer and 41,780 deaths will occur in the United States 
in 2016, thereby making it the fourth leading cause of cancer deaths for both men 
and women.1 Given the poor outcomes, significant efforts have been undertaken 
to improve the treatment of pancreatic cancer. The only curative therapy is resec-
tion; however, only 15%–20% of patients present with resectable disease. Patients 
are often asymptomatic initially and symptoms develop only after local or distant 
progression.2 Moreover, even among the favorable patients who undergo surgical 
resection, the median overall survival is ~20 months despite the use of adjuvant 
chemotherapy or chemoradiation.3–5
Patients with unresectable, locally advanced pancreatic cancer have limited treat-
ment options, and typically chemotherapy and/or radiotherapy are the primary treatment 
modalities. Treatment strategies such as chemotherapy followed by chemoradiation 
(in patients without disease progression on chemotherapy) result in a median overall 
survival of 15–16 months.6,7 In patients with unresectable pancreatic cancer, progres-
sive local and distant disease leads to mortality. A Johns Hopkins rapid autopsy study 
showed that among 55 patients with stage III disease, 72% had metastatic disease and 
28% had local-only disease.8 These patterns of progression suggest a need for improved 
local and systemic treatments. Moreover, patients with even limited metastatic disease 
burden in this study often died due to progressive local disease.
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Given the low rates of local control with chemotherapy 
or chemoradiation, the use of stereotactic body radiation 
therapy (SBRT; perhaps best described as hypofractionated 
image-guided radiotherapy), comprising treatment with five 
fractions of radiation or less, has become an area of active 
investigation. SBRT represents an alternative to conven-
tionally fractionated chemoradiotherapy in the treatment of 
locally advanced pancreatic cancer. There are additional, 
although limited, data for SBRT as a complementary treat-
ment for resectable patients in the neoadjuvant and adjuvant 
settings. We review the historical development, techniques, 
and clinical outcomes of SBRT for pancreatic cancer. 
In addition, practical considerations in implementing this 
modality and the areas of active investigation and future 
avenues for pancreatic SBRT are discussed.
Clinical evolution of SBRT in the 
treatment of pancreatic cancer
SBRT implements highly conformal and precise delivery of 
radiotherapy to achieve ablative doses to treatment volumes 
over the course of one to five fractions. This technique is 
well established in the treatment of central nervous system 
and pulmonary malignancies and has been increasingly 
adopted as a potential approach in treating abdominal 
cancers, including liver neoplasms such as hepatocellular 
carcinoma, cholangiocarcinoma, and liver metastases, as 
well as pancreatic cancer.9 To date, there have been several 
early phase, prospective studies characterizing the safety and 
efficacy of SBRT in the treatment of patients with pancreatic 
cancer, primarily in the locally advanced, unresectable setting 
(Table 1). In addition, numerous retrospective series have 
been published.
The use of SBRT in the treatment of patients with locally 
advanced pancreatic cancer was first reported in a Phase I 
dose escalation study from investigators at Stanford in 2004. 
Fifteen patients were treated with single-fraction SBRT 
with doses escalating from 15 Gy to 20 Gy to 25 Gy using 
the Accuray CyberKnife system (Accuray Inc., Sunnyvale, 
CA, USA).10 No dose-limiting toxicity was observed and 
there were no local recurrences with a median follow-up 
of 11 months. Despite high local control rates, all patients 
progressed distantly. These results prompted a Phase II study 
of 45 Gy intensity-modulated radiotherapy (IMRT) with con-
current 5-fluorouracil followed by an SBRT boost of 25 Gy 
in one fraction.11 This study also showed high rates of local 
control (94% 1-year freedom from local recurrence with a 
median follow-up of 23 weeks) but with much higher rates 
of toxicity, including two patients who experienced grade 3 
acute gastrointestinal (GI) toxicity (gastroparesis requiring 
parenteral support; one before SBRT and one after SBRT). 
Despite enhanced rates of local control, patients continued to 
develop distant metastases with corresponding poor survival 
rates (median overall survival of 33 weeks).
Given this pattern of distant recurrence, follow-up studies 
from this group delivered gemcitabine before and following 
SBRT, again with 25 Gy in one fraction.12 Sixteen patients 
with locally advanced pancreatic cancer were included in 
this study with a similar outcome profile: good local control 
(three patients with local progression at 14, 16, and 21 months 
after SBRT) but accompanied by a high rate of duodenal 
toxicity, with five ulcers, one duodenal stenosis, and one 
perforation (44% grade 2+ and 12.5% grade 3+).
Given these toxicities, a follow-up Phase II study from 
Stanford of 20 patients with locally advanced pancreatic 
cancer was conducted with priority given to meeting 
duodenal constraints.13 This study also transitioned treat-
ment to linear accelerator (linac)-based SBRT with IMRT. 
The protocol continued to use a 25 Gy single fraction 
Table 1 Prospective studies of stereotactic body radiation therapy for pancreatic cancer








Koong et al10 15–25 Gy/1 fx 15 LA or LR 100 11 0 NR
Koong et al11 45 Gy iMRT +5-FU → 25 Gy/1 fx 16 LA 94 8.3 13 NR
Høyer et al16 15 Gy ×3 22 LA 57 5.4 79 grade 2+ 94
Schellenberg et al12 Gemcitabine → 25 Gy/1 fx → gemcitabine 16 LA 100 11.4 6 47
Polistina et al17 10 Gy ×3 23 LA 50 10.6 0 0
Schellenberg et al13 Gemcitabine → 25 Gy/1 fx → gemcitabine 20 LA 94 11.8 5 20
Tozzi et al46 Gemcitabine → 45 Gy/6 fx or 36 Gy/6 fx 30 LA or LR 77 11 0 0
Gurka et al18 Gemcitabine → 25 Gy/5 fx → gemcitabine 10 LA 40 12.2 0 0
Herman et al19 Gemcitabine → 33 Gy/5 fx 49 LA 78 13.9 12 11
Note: Arrows demonstrate sequence of the treatment regimen.
Abbreviations: 5-FU, 5-fluorouracil; fx, fraction; Gy, gray; IMRT, intensity modulated radiotherapy; LA, locally advanced; LR, locally recurrent; NR, not reported; OS, 
overall survival.




SBRT for pancreatic cancer
SBRT regimen. At most, 5% of the duodenum was permit-
ted to receive $22.5 Gy, and half or less of the duodenum 
at the planning target volume (PTV) was permitted to 
receive $12.5 Gy. PTV margins of 2–5 mm were used 
in this study. The local control was 94% at 1-year with a 
single grade 4 toxicity (duodenal perforation [5%]), and 
three patients developed duodenal ulcers (grade 2, 15%). 
The authors note that the rate of late gastrointestinal toxicity 
was comparable to conventionally fractionated chemoradio-
therapy and intraoperative electron beam radiotherapy.14,15
In parallel with these studies, fractionated SBRT has been 
investigated in European prospective studies. A multiinsti-
tutional Phase II study in Denmark investigated linac-based 
SBRT using 45 Gy in three fractions in a cohort of 22 patients. 
Despite fractionation, the study found poor local control rates 
(57% at 1 year) and little palliative benefit with high rates of 
acute GI toxicity (79% grade 2+ toxicity following SBRT).16 
In this study, patients were treated using abdominal compres-
sion and more generous PTV margins (5 mm in the transverse 
and 1 cm in the craniocaudal direction) than described in 
the Stanford series. Additionally, peritumoral edema was 
included in the target. These larger treatment volumes may, 
in part, account for the higher rates of toxicity seen in this 
study compared to the Stanford series.
Polistina et al reported their prospective experience using 
CyberKnife treatments for 23 patients receiving 30 Gy in 
three fractions coupled with 6 weeks of induction and adju-
vant gemcitabine. Volumes for this study were defined as per 
the Stanford SBRT protocol, and the study yielded modest 
rates of toxicity with no grade 2+ acute or late toxicities with 
good rates of local response.17 Five patients were assessed 
as having resectable disease following SBRT. Three of 
these patients underwent resection, two patients had an R0 
resection without complication, and one patient achieved a 
pathologic complete response (pCR). Of note, the 1-year 
local control in this study was 50%, lower than other reports 
from studies incorporating SBRT.
Similarly, Georgetown University investigators per-
formed a feasibility trial investigating the safety of full-dose 
gemcitabine with SBRT delivered with 25 Gy in five daily 
fractions during week 4 of cycle 1 using CyberKnife treat-
ments. In their cohort of 10 evaluable patients, a 40% 1-year 
local control without acute grade 3 toxicity was reported.18 
Moreover, this study demonstrated the feasibility of SBRT 
employed with full-dose gemcitabine.
Most recently, a multiinstitutional, prospective Phase II 
study was undertaken at Johns Hopkins, Stanford, and 
Memorial Sloan-Kettering, using a multifraction technique 
in patients with locally advanced pancreatic cancer.19 The 
primary endpoint of this study was to define the grade 2 
toxicity rates of a fractionated regimen and compare this to 
the single fraction results from Stanford.12 Forty-nine patients 
received 33 Gy in five fractions with up to three doses of 
gemcitabine weekly before SBRT, followed by additional 
gemcitabine until disease progression. Radiation treatment 
plans were centrally reviewed by a principal investigator. 
Additionally, fiducial marker placement, respiratory motion 
management, and adherence to predefined dose constraints 
were required. Study results were consistent with previ-
ously reported studies, with 79% local control at 1 year and 
a median overall survival of 13.9 months. A lower rate of 
toxicity was reported versus single fraction treatment, with 
one acute (2%) and three late (6%) grade 3+ GI toxicities. 
Quality of life endpoints from this study are pending, but the 
investigators reported no decline in the quality of life follow-
ing SBRT, with significant improvement in pain scores.20
Although prospective data demonstrate safety and accept-
able clinical outcomes in the treatment of locally advanced 
and unresectable pancreatic cancer, there is significantly 
less experience for SBRT in the neoadjuvant and adjuvant 
settings. While surgery remains the only curative option 
in these patients, overall outcomes are poor.3 The Harvard 
group conducted a Phase I study of 15 patients with resect-
able pancreatic cancer using proton therapy with dose 
escalating hypofractionationated treatment with concurrent 
capecitabine in the preoperative setting, reaching a final dose 
level of 25 Gy in five fractions without encountering any 
dose-limiting toxicities.21 Of note, the treatment volumes in 
this study included the primary tumor and regional nodes 
(celiac, porta hepatis, superior mesenteric artery and vein, 
and paraaortic through the third portion of the duodenum). 
This led to a Phase II study of 35 patients using the 25 Gy 
in five fractions regimen neoadjuvantly, showing a 4.1% 
grade 3 acute toxicity. Among the total 50 patients (from 
the Phase I and II studies), 39 patients underwent resec-
tion, with 31 (84%) patients achieving R0 resection without 
30-day mortality or anastamotic leak.22 The median survival 
was 27 months with a median follow-up of 38 months, and 
16% of those patients undergoing surgical resection had a 
locoregional recurrence.
Approximately 30% of patients present with borderline 
resectable pancreatic cancer. Although data are variable, a 
meta-analysis of Phase II studies showed that one-third of 
patients with borderline resectable or unresectable disease 
receiving neoadjuvant therapy were able to undergo surgical 
resection.23 Patients with borderline resectable disease are 





usually treated with neoadjuvant therapy either chemotherapy 
or chemoradiation.6 There are few retrospective analyses 
describing the experience of SBRT in this setting.24–26 Among 
these, Mellon et al described a series of 159 patients, includ-
ing 110 patients with borderline resectable pancreatic cancer. 
Patients received a median dose of 30 Gy to the tumor and 
40 Gy to the vessel–tumor interface in five fractions. For 
the patients with borderline resectable disease, 51% of the 
patients were able to undergo surgical resection, with 96% 
of them achieving margin-negative resection.25 Four patients 
(7%) had a pCR. Similarly, a retrospective review of the 
Johns Hopkins experience included 19 out of 88 total 
patients with unresectable or borderline resectable disease 
who were able to undergo surgical resection. Of them, 84% 
of the patients had margin-negative resection and 16% of 
the patients had pCR.26
In the postoperative setting, a single retrospective study 
from the University of Pittsburgh reported on the outcome of 
24 patients receiving adjuvant SBRT.27 Among these patients, 
all had close or positive margins, with 96% of patients 
receiving single fraction SBRT with a median dose of 24 Gy. 
No patients experienced grade 3+ acute or late toxicities, and 
freedom from local progression was 66% at 1 year.
Technical considerations
SBRT requires highly conformal and precise radiation deliv-
ery with significant imaging and technical requirements. 
Early experiences of SBRT in the treatment of pancreatic 
cancer patients from the Stanford experience used frame-
less stereotactic radiosurgery with the Accuray CyberKnife 
system. Since then, linac-based SBRT has been studied with 
similar outcomes (Figure 1).
Simulation
Prior to simulation, fiducial markers are often placed in the 
tumor or in close proximity to the tumor to assist in target 
identification at simulation and treatment. These are typically 
placed via endoscopic ultrasound just prior to simulation. At 
time of radiation simulation, an upper Vac-Lok (CIVCO Med-
ical Solutions, Coralville, IA) on an indexed wingboard, alpha 
cradle, or body fix is created for immobilization. Assessment 
and management of respiratory motion is recommended. 
Figure 1 Workflow for pancreas stereotactic body radiation therapy.
Notes: (A) Fiducial marker placement by endoscopic ultrasound. (B) Simulation with immobilization and motion management (body fix and Varian Real-Time Position 
Management™; Palo Alto, CA, USA). (C) Treatment planning. (D) Image verification by kV fluoroscopy (pictured) or cone beam computed tomography.
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A four-dimensional computed tomography (CT) can be 
helpful to assess the magnitude of tumor motion with normal 
respiration. Motion management is challenging for abdominal 
tumors as there can be significant intrafraction and interfrac-
tion variations due to respiration that can be in the order of 
2–3 cm.28 If motion is .3–5 mm, respiratory motion manage-
ment should generally be implemented with active breathing 
control, breath hold (ideally in end-expiration), or gating 
breath holding methods to minimize treatment volumes. 
There are data to suggest that end-expiration may allow for 
the most favorable anatomy to maximize therapeutic ratio.29 
At our institution, we have not routinely used abdominal 
compression since this method has the potential to displace 
the duodenum and bowel toward the target volumes.
Patients are imaged using CT ± magnetic resonance imag-
ing (MRI) in supine position with arms up. Some institutions 
perform a positron emission tomography (PET)/CT simulation 
and utilize this for tumor response assessment post-SBRT. 
Prior retrospective analyses have found correlations between 
pre-SBRT PET parameters and clinical outcomes (discussed 
in “Future directions” section).30,31 The use of oral and IV 
contrast for better delineation of target and normal structures 
is recommended. Simulation imaging is typically performed 
with at least dual phasic contrast imaging with arterial and 
portal venous phases timed by bolus tracking software to 
appropriately time imaging with contrast administration. 
Use of multiphasic imaging allows greater delineation of the 
tumor, as these typically are seen best in contrast in the portal 
venous phase, with nonenhancement over the background of 
enhancing pancreatic tissues.32
Definition of treatment volumes
Gross tumor volume is identified based on simulation CT/MRI 
as well as other diagnostic imaging. With multiphasic imaging, 
the primary tumor and adjacent nodal disease is included in 
the gross target volume for each imaging sequence. These are 
combined to comprise an internal target volume (ITV), which 
should approximate the tumor motion identified on four-dimen-
sional CT (if free breathing is used). The ITV is then expanded 
by 2–3 mm margin to the PTV. The PTV is then modified based 
on adjacent normal structures such as the duodenum, stomach 
and bowel and with additional coverage of regions away from 
the normal tissues (particularly in the retroperitoneum and 
along the vasculature). With a 2 mm margin between the PTV 
and normal organs, there may be selective underdosing of the 
PTV to respect normal tissue constraints. Additionally, an ITV 
contour for the fiducial markers or adjacent surgical clips may 
assist target alignment at the time of treatment.
Treatment planning
Ideally IMRT or volumetric modulated arc therapy should 
be used to deliver necessary doses to the target while spar-
ing normal tissues. Use of flattening filter-free SBRT can 
decrease treatment time.33 GI structures, particularly the 
duodenum, are the main sources of potential toxicity. In the 
Stanford experience, patients undergoing 25 Gy ×1 had a 
higher rate of duodenal toxicity correlating with V15, V20, 
and Dmax.13 A lower rate of toxicity was seen in the multi-
institutional, Phase II experience that used a dose of 33 Gy 
in five fractions.19 The normal tissue constraints described 
in this study are as follows: proximal duodenum, stomach, 
and small bowel with V15 Gy ,9 cc, V20Gy ,3 cc, and 
V33 Gy ,1 cc; liver V12 Gy ,50%; combined kidneys 
V12 ,75%; and spinal cord V8 Gy ,1 cc.
Treatment delivery
Image-guided radiation therapy by kV or fluoroscopic 
on-board imaging and cone beam CT to verify the target 
and normal tissues prior to delivery of treatment are recom-
mended. Fluoroscopy for alignment based on the fiducial 
markers is particularly important in target assessment as 
there are data to suggest that cone beam CT may underes-
timate the abdominal motion of pancreatic lesions.28 Cone 
beam CT should primarily be used to evaluate the location 
of normal tissues. Multiple breath holds may be required 
to acquire cone beam CT for patients where respiratory 
motion management is implemented. During treatment, we 
favor the use of prophylactic proton pump inhibitors and 
antiemetics.
Future directions
Selecting appropriate candidates for SBRT remains an area of 
active investigation. There are data to suggest that patterns of 
recurrence may be predicted based on radiographic, labora-
tory, or pathologic biomarkers. Given the promise of SBRT 
as a local therapy, these methods may allow better identifica-
tion of patients who would benefit from local therapy. PET 
para meters have been of emerging interest in multiple disease 
sites, and metabolic tumor volume and total lesion glycolysis 
have been metrics of active investigation. Pre-SBRT SUVmax 
has previously been reported to be correlated with survival 
and progression-free survival.30 A subcohort of the previously 
mentioned multiinstitutional study had baseline PET imaging 
that was analyzed, finding a correlation between metabolic 
tumor volume and total lesion glycolysis with overall survival 
for patients undergoing SBRT.31 Similarly, laboratory bio-
markers may have some utility with recent retrospective data 





to suggest correlation between pre-SBRT albumin levels and 
neutrophil–lymphocyte ratio with overall survival.34
Pathologic biomarkers are another active area of investi-
gation. A rapid autopsy study from Johns Hopkins showed a 
correlation between the loss of SMAD4/DPC4 expression and 
greater propensity for metastatic disease.8 Within the same 
pathway, high transforming growth factor-β1 plasma levels, 
the SMAD4 single-nucleotide polymorphism rs11354983, 
and high transforming growth factor-βR2/SMAD4 expres-
sion are similarly correlated with poor outcomes.35 SMAD4 
is a stratification factor, alongside CA19-9 levels, in ongoing 
cooperative group studies.36
Finally, there is a need for more effective adjunct thera-
pies given the low overall survival and high rates of distant 
progression despite reasonable local control. Thus, incorpo-
rating surgical resection and systemic therapies to comple-
ment SBRT are active areas of investigation. In addition to 
prospective studies of SBRT as a neoadjuvant37 and adjuvant 
therapy,38 studies are actively combining traditional chemo-
therapy with neoadjuvant SBRT, such as FOLFIRINOX39,40 
and gemcitabine/nab-paclitaxel.41 Beyond chemotherapy, 
there is also an increasing interest in the role of immune thera-
pies, with ongoing studies of whole cell tumor vaccines.42–44 
SBRT has spurred much interest as a potential complement 
in the form of immunosensitization in many disease sites and 
may further enhance these systemic therapies.45
Conclusion
There is a growing experience in the use of SBRT for the treat-
ment of patients with pancreatic cancer. At present, there has 
been no prospective comparison of SBRT versus convention-
ally fractionated chemoradiation. The delivery of high-dose, 
highly conformal, and precise radiotherapy enables ablative 
therapy to unresectable pancreatic lesions, with data suggesting 
local control rates of at least 78%. While continued advance-
ments in imaging, target localization, and dosimetric parameters 
should improve toxicity profiles, further study with systemic 
therapies is required to improve the poor survival outcomes.
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